BioCentury
ARTICLE | Clinical News

EC1456: Phase I data

March 9, 2015 7:00 AM UTC

Data from 16 evaluable patients with metastatic or locally advanced solid tumors who failed to respond to standard therapy if available in the first part of an open-label, dose-escalation, U.S. Phase I trial showed that twice-weekly 0.5, 1, 1.5 and 2 mg/m 2 and once-weekly 1.5, 2, 2.5, 3.5 and 4.5 mg/m 2 doses of EC1456 were generally well tolerated with no treatment-related deaths, serious adverse events, dose modifications or grade 4 toxicities reported. There was a dose-limiting toxicity (DLT) of grade 3 infusion reaction in a patient receiving once-weekly 4.5 mg/m 2 EC1456. In 14 evaluable patients for response, there were 8 cases of stable disease. Data were presented at the International Congress on Targeted Anticancer Therapies in Paris. ...